ESMO 2022 | Final results of the phase 3 DATA trial assessing aromatase inhibition in HR+ breast cancer

Vivianne Tjan-Heijnen, MD, PhD, Maastricht University, Maastricht, the Netherlands, discusses the final analysis of the Phase III DATA (NCT00301457) trial investigating the use of various durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2-3 years of adjuvant tamoxifen. The results indicate aromatase inhibition cannot be recommended beyond 5 years of sequential therapy in hormone receptor-positive breast cancer, it may considered for node-positive, ER- and PR-positive tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.